Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 2

Withdrawn

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: NCT00387972
• Lead Sponsor: GlaxoSmithKline

Brief Summary

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo, taken once daily in patients with Type 2 diabetes mellitus.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-10-12
• Study First Submitted QC: 2006-10-12
• Study First Posted: 2006-10-13
• Primary Completion: 2007-10
• Study Completion: 2007-10
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-15
• Last Update Posted: 2015-04-17

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from baseline in blood glucose regulation after 26 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
Change from baseline in glycemic parameters, insulin, body weight and waist circumference, and safety measures

Trial Locations

Locations (1)

GSK Clinical Trials Call Center; 🇺🇸 Weber City, Virginia, United States